Bertaut v. United States

852 F. Supp. 523, 1994 U.S. Dist. LEXIS 3910, 1994 WL 224837
CourtDistrict Court, E.D. Louisiana
DecidedMarch 30, 1994
Docket91-4215
StatusPublished

This text of 852 F. Supp. 523 (Bertaut v. United States) is published on Counsel Stack Legal Research, covering District Court, E.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bertaut v. United States, 852 F. Supp. 523, 1994 U.S. Dist. LEXIS 3910, 1994 WL 224837 (E.D. La. 1994).

Opinion

FINDINGS OF FACT AND CONCLUSIONS OF LAW

McNAMARA, District Judge.

This matter was tried to the Court without a jury on March 21 and 22,1994. Now, after considering the evidence and the memoranda of counsel, the Court enters the following Findings of Fact and Conclusions of Law.

1. This action is brought under the Federal Tort Claims Act, 28 U.S.C. §§ 1346(b), 2671 et seq., by Plaintiffs, Vinie Bertaut and John Bertaut, for the acts and omissions of the United States under the National Swine Flu Immunization Program of 1976, 42 U.S.C. § 247b(j)-(Z).

2. The Swine Flu Immunization Program was enacted into law by Congress and the President in 1976 on an emergency basis in an effort to avoid a potential flu epidemic.

3. The testimony and evidence showed by a preponderance of the evidence that Plaintiff, John Bertaut, received the swine flu vaccination on December 7, 1976. (See Trial Exhibit No. A-5). This Plaintiff does not claim that he had any ill side effects from this vaccination.

4. The Court defers on ruling whether Plaintiff, Vinie Bertaut (“Mrs. Bertaut”), proved by a preponderance of the evidence whether she actually received the swine flu vaccination in November or December 1976 as she alleges. 1

*524 5. While Mrs. Bertaut allegedly received the swine flu vaccine in November or December 1976, she did not file this lawsuit until November 15,1991. (Mrs. Bertaut previously filed an administrative complaint on March 20, 1991 and it was denied on May 16, 1991. See Trial Exs. A-10 & 11). However, the Court also defers ruling on whether this lawsuit is barred by the two years statute of limitations set forth in 28 U.S.C. § 2401(b). 2

6. Guillain-Barre Syndrome (“GBS”) is a medical condition referring to the destruction of insulation around the peripheral nerves causing them to become dysfunctional; this process is known as demyelination.

7. Mrs. Bertaut claims that she had an acute episode of GBS in December 1976 and several recurring episodes of GBS in subsequent years. However, even if Mrs. Bertaut received the swine flu vaccine as she alleges and her claim is not time barred, the court nevertheless finds that Plaintiff has failed to prove by a preponderance of the evidence that she developed either acute or chronic recurring GBS, much less that she developed GBS as a result of allegedly receiving the swine flu vaccine.

8. The mere “possibility” (which is what the evidence shows) that Mrs. Bertaut developed any acute or chronic recurring GBS from any cause, known or unknown, is legally insufficient to meet her burden of proof.

9. The mere “possibility” (which is what the evidence shows) that Mrs. Bertaut developed acute or chronic recurring GBS as a *525 result of the alleged swine flu vaccination is likewise legally insufficient to meet her burden of proof.

10. The cause of GBS in unknown but it usually is triggered by some type of antecedent event, such as a respiratory or gastrointestinal infection and surgery. The swine flu vaccine is also known to be statistically associated with GBS. A recurring episode of GBS is rare, and multiple recurring episodes of GBS are even rarer. Drs. Patricia Cook, Charles Poser and Barry Arnason (neurologists) testified that recurring GBS cases comprise only 1-5% of all GBS eases. 3

11. Before December 1976, Mrs. Bertaut had a history of asthma which on occasion required treatment with subcutaneous epinephrine.

12. Although there is no laboratory test (biochemical or electrodiagnostic) which conclusively diagnoses GBS, 4 the overwhelming medical evidence and testimony presented at Trial indicates that GBS is not difficult to diagnose, even when it is in a chronic recurring stage. In response to the court’s inquiry, Dr. Wayne Buffat, an internist, explained that in today’s world of specialized medicine, many physicians “defer” to neurologists for the diagnosis and/or treatment of GBS, but GBS is relatively easy to diagnose, even by internists such as himself, based upon the patient’s clinical presentation of ascending paralysis and diminished reflexes.

13. Two particular symptoms are required for diagnosing GBS: (1) progressive motor weakness of the lower extremities; and (2) areflexia or diminished reflexes.

14. While these two “required” symptoms, along with other “supportive” symptoms, were identified by the National Institute of Neurological and Communicative Disorders and Stroke (“NINCDS”) in 1978 to help physicians recognize the syndrome’s diagnostic boundaries (Trial Ex. CC-5), these two required symptoms were well known and routinely used by physicians before 1978 in diagnosing GBS.

15. The first required symptom in diagnosing GBS, i.e., progressive motor weakness, may vary in degree and affects more than one limb, usually the lower extremities but sometimes all four limbs. GBS is also known as “ascending paralysis” as the weakness or paralysis is known to travel upwards in the lower extremities.

16. The second required symptom in diagnosing GBS, i.e., areflexia or diminished reflexes, is an objective measurement made by the clinician. A normal reflex is measured at 2 +; areflexia is measured at 0 +; a diminished reflex is measured at 1 +; and a hyper-reflex is measured at 3 + . In response to the court’s inquiry, Dr. Frank Guidry explained that different, trained physicians would report the same measurement of a given patient’s reflexes if these physicians would be asked to measure the reflexes at a given time. In other words, one would not expect reflex measurements to vary from physician to physician.

17. Other symptoms or features which may be helpful in diagnosing GBS include: various sensory changes; protein in the cerebrospinal fluid; abnormal electrodiagnostic tests such as an electromyogram and nerve conduction test.

18. On December 25, 1976, Mrs. Bertaut presented at Slidell Memorial Hospital (“SMH”), complaining of extreme weakness. (Trial Exs. H 1-4, SMH medical records). She was treated by Dr. Frank Guidry (family practitioner), who consulted Dr. Wayne Buffat (internist). These physicians were unable to detect any objective findings of weakness or reflex abnormality.

Dr. Guidry testified that Mrs. Bertaut’s complaints of difficulty in walking were inconsistent with her ability to get in and out of bed without difficulty, and her reflexes were 3 + . (Trial Ex. H-4, Progress note of *526 12/29/76). Dr. Buffat reported her reflexes were 8+ and he found “no evident muscle weakness.” (Trial Ex. H-3, p.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
852 F. Supp. 523, 1994 U.S. Dist. LEXIS 3910, 1994 WL 224837, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bertaut-v-united-states-laed-1994.